Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.39 |
| ▸ | CA2 | P00918 | 4/20 | 0.39 |
| ▸ | CA9 | Q16790 | 4/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | OGA | O60502 | 5/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HEXB | P07686 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30980682 | 0.93 | CA1 (0.35) | CA1CA2CA9CA12CA14 | |
| SCHEMBL30980784 | 0.88 | MAPK1 (0.38) | OGAMAPK1HEXB | |
| SCHEMBL30980703 | 0.85 | B4GALT1 (0.38) | CA1CA2CA9CA12CA14 | |
| SCHEMBL30980577 | 0.84 | MAPK1 (0.36) | OGAMAPK1HEXB | |
| SCHEMBL30980642 | 0.79 | MAPK1 (0.43) | CA1CA2CA9MAPK1 | |
| SCHEMBL30980649 | 0.78 | MAPK1 (0.43) | MAPK1 | |
| SCHEMBL30980709 | 0.76 | MAPK1 (0.41) | OGAMAPK1HEXB | |
| SCHEMBL30980606 | 0.75 | MAPK1 (0.47) | CA1CA2CA9OGAMAPK1 | |
| SCHEMBL30980757 | 0.74 | MAPK1 (0.46) | MAPK1 | |
| SCHEMBL30980773 | 0.74 | MAPK1 (0.40) | OGAMAPK1HEXB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4651902-A2 | ASGPR BINDING COMPOUNDS AND CONJUGATES | Lycia Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4651901-A1 | CYCLING LYSOSOMAL TARGETING ANTIBODY CONJUGATES | Lycia Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| WO-2025035040-A1 | LYSOSOMAL TARGETING BIFUNCTIONAL MOLECULES FOR DEGRADATION OF MUSCLE-SPECIFIC KINASE AUTOANTIBODIES | LYCIA THERAPEUTICS, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| WO-2024155747-A2 | ASGPR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. (US) | 2024-07-25 | — | — | WO | disclosed |